×

Najarian: Buy this biotech stock

Celgene
Kristoffer Tripplaar | AP
Celgene

CNBC "Halftime Report" trader Jon Najarian purchased shares of Celgene for his model portfolio Monday as the stock recovered from a recent low.

Celgene is a leading global biotech company focused on therapies for cancer and inflammatory diseases.

In other moves, Najarian sold his model portfolio positions in BorgWarner and Precision Drilling.

Here's why Najarian made Celgene one of his top picks.